事件。7月15日,中国生物制药公告,将以约5亿美元的总价收购上海礼新医药95.09%股权,加上此前参与礼新C轮融资时既已取得的4.91%股权,交易完成后,礼新医药将成为中国生物制药全资子公司。礼新医药主要研发和管理团队也将连同其双抗、ADC等研发平台一起,加入中国生物制药。根据公告,礼新医药95.09%股权出售对价为不超过9.5亿美元,剔除礼新持有的4.5亿美元现金后,中国生物制药收购的付款金额约...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.